Bausch + Lomb (NYSE:BLCO) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Bausch + Lomb (NYSE:BLCO) released its earnings results on Wednesday. The company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03), Zacks reports. The company had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.38 billion. Bausch + Lomb had a positive return on equity of 2.42% and a negative net margin of 6.13%.The firm’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter last year, the business earned $0.25 earnings per share.

Here are the key takeaways from Bausch + Lomb’s conference call:

• Reported record Q4 revenue of $1.405 billion and full‑year revenue of $5.101 billion, with Q4 Adjusted EBITDA of $330 million (up 27%) and a 23.5% EBITDA margin, highlighting strong operating leverage.
• 2026 guidance calls for full‑year revenue of $5.375–$5.475 billion (5%–7% constant‑currency growth) and Adjusted EBITDA of $1.0–$1.05 billion, implying continued margin expansion toward the company’s multi‑year targets.
• MIEBO drove blockbuster growth (FY revenue $316 million, Q4 $112 million, prescriptions >2 million) and management now sees peak sales potential exceeding $600 million, underpinning dry‑eye momentum.
• Pipeline and R&D milestones progressed: CE Mark submission for the Silera femtosecond laser expected soon and a first external study of a new bioactive contact‑lens material met expectations, keeping a 2028 launch timeline on track but still subject to further trials.
• Surgical business recovery post‑enVista recall: company says it returned to prior market levels ahead of plan, with premium IOLs up ~20% in Q4, supporting higher‑margin mix in implantables.

Bausch + Lomb Stock Performance

Shares of BLCO traded up $0.27 during trading hours on Thursday, hitting $17.94. The stock had a trading volume of 207,800 shares, compared to its average volume of 385,737. The firm has a 50-day moving average price of $17.04 and a 200 day moving average price of $15.81. Bausch + Lomb has a fifty-two week low of $10.45 and a fifty-two week high of $18.08. The firm has a market capitalization of $6.36 billion, a price-to-earnings ratio of -20.71, a PEG ratio of 1.03 and a beta of 0.61. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.98 and a current ratio of 1.51.

Institutional Investors Weigh In On Bausch + Lomb

Several hedge funds have recently modified their holdings of BLCO. Northwestern Mutual Wealth Management Co. increased its stake in shares of Bausch + Lomb by 729.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after purchasing an additional 2,042 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Bausch + Lomb by 104.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after buying an additional 1,136 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Bausch + Lomb by 31.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after buying an additional 1,403 shares during the period. Focus Partners Wealth purchased a new position in shares of Bausch + Lomb during the 3rd quarter valued at approximately $170,000. Finally, JPMorgan Chase & Co. acquired a new stake in Bausch + Lomb in the 2nd quarter valued at $200,000. 11.07% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Revenue topped estimates and management reiterated full-year revenue guidance of roughly $5.4B–$5.5B, supporting growth expectations and helping shares rise despite the EPS miss. Read More.
• Positive Sentiment: Company framed the quarter as part of a “record year” and signaled a push toward profitable growth on the conference call — messaging that reassures investors focused on margin recovery and sustainable revenue expansion. Read More.
• Positive Sentiment: Management highlighted product innovation initiatives (CEO promoted a new contact-lens technology) and internal incentives tied to AI literacy, which investors may view as long-term catalysts for differentiation and efficiency. Read More. Read More.
• Neutral Sentiment: Stifel Nicolaus maintained a Hold rating on BLCO — a sign of mixed analyst views that can temper volatility but not strongly move consensus. Read More.
• Neutral Sentiment: Full earnings call transcripts and recaps are available for detail on segment performance and margin drivers; these are useful for investors digging into the drivers behind the top-line beat. Read More. Read More.
• Negative Sentiment: EPS missed consensus ($0.32 vs. $0.35) and the company reported a negative net margin for the quarter, which raises near-term profitability concerns and explains part of analyst caution. Read More.
• Negative Sentiment: Bank of America reiterated a Sell rating and set a $15 price target, citing structural and margin headwinds — a high-profile negative analyst view that could cap upside until margins visibly improve. Read More.

Analyst Ratings Changes

BLCO has been the subject of a number of research analyst reports. Barclays raised their target price on Bausch + Lomb from $17.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $18.00 price objective on shares of Bausch + Lomb in a research note on Thursday. The Goldman Sachs Group reiterated a “neutral” rating and issued a $19.00 target price on shares of Bausch + Lomb in a research report on Friday, January 9th. Royal Bank Of Canada raised their price target on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 27th. Finally, Wall Street Zen upgraded shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $17.85.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.